Mesa Laboratories, Inc. shares are trading lower after the company announced its Clinical Genomics Division customer, Sema4, will exit the reproductive health screening business. Sema4 informed the company it will reduce the quantity of orders in Q3.
Bill Haddad - Nov 22, 2022, 10:46AM